Last10K.com

Nektar Therapeutics (NKTR) SEC Filing 8-K Material Event for the period ending Wednesday, September 25, 2019

Nektar Therapeutics

CIK: 906709 Ticker: NKTR

View differences made from one to another to evaluate Nektar Therapeutics's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Nektar Therapeutics.

Continue

Assess how Nektar Therapeutics's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Nektar Therapeutics's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Ticker: NKTR
CIK: 906709
Form Type: 8-K Corporate News
Accession Number: 0001213900-19-019363
Submitted to the SEC: Tue Oct 01 2019 8:15:32 AM EST
Accepted by the SEC: Tue Oct 01 2019
Period: Wednesday, September 25, 2019
Industry: Pharmaceutical Preparations
Events:
  1. Event for Officers

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/nktr/0001213900-19-019363.htm